Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival pharminent April 13, 2026
Regulatory IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy pharminent April 13, 2026
M&A / Deals AbbVie enters world of pain in up to $715M deal with China’s Haisco pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors pharminent April 10, 2026
Policy / Pricing RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders pharminent April 10, 2026
Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch pharminent April 10, 2026
Regulatory GSK again pulls application for leucovorin, touted by FDA as potential autism treatment pharminent April 10, 2026
M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research pharminent April 10, 2026
M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation pharminent April 10, 2026
Other Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers pharminent April 10, 2026
Regulatory Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar pharminent April 9, 2026
Commercial Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk pharminent April 9, 2026
Other Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic pharminent April 9, 2026
M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb pharminent April 9, 2026
Manufacturing Innovent’s CDMO gets green light to make biologics at large Chinese plant pharminent April 9, 2026
M&A / Deals Roche sticks with C4T, adding up to $1B for molecular glue partnership pharminent April 9, 2026
M&A / Deals Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors pharminent April 9, 2026
Policy / Pricing The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) pharminent April 9, 2026
Regulatory FDA seeks permanent future for rare pediatric priority review vouchers pharminent April 9, 2026
M&A / Deals With 3 quick buyouts, Gilead leans into its latest transformation pharminent April 8, 2026
M&A / Deals Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities pharminent April 8, 2026